Chart: "Wild Cards: NMEs and New Biologics That Are Still Pending After FDA Missed User Fee Goal Dates In 2008"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Wild Cards: NMEs and New Biologics That Are Still Pending After FDA Missed User Fee Goal Dates In 2008